Clinical Trials on Autoimmune Hemolytic Anemia in Belgium

Total 724 results

Sanofi

Terminated

Safety, Pharmacokinetics, and Efficacy of Subcutaneous Isatuximab in Adults With Warm Autoimmune Hemolytic Anemia (wAIHA)

Warm Autoimmune Hemolytic Anemia (wAIHA)

United Kingdom, Belgium, Netherlands, France, United States, Germany, Hungary, Italy
Incyte Corporation

Terminated

Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic Anemia (PATHWAY)

Warm Autoimmune Hemolytic Anemia (wAIHA)

Spain, United States, Austria, Belgium, Canada, France, Germany, Israel, Italy, Japan, Netherlands, Poland, United Kingdom
Rigel Pharmaceuticals

Enrolling by invitation

A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

Warm Antibody Autoimmune Hemolytic Anemia

Spain, United States, Australia, Norway, Belarus, Germany, Netherlands, Belgium, Austria, Bulgaria, Czechia, France, Georgia, Italy, Russian Federation, Serbia, Ukraine, United Kingdom
Rigel Pharmaceuticals

Completed

A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA

Warm Antibody Autoimmune Hemolytic Anemia

United States, Spain, Canada, Australia, Norway, France, Belarus, Germany, Netherlands, Belgium, United Kingdom, Austria, Czechia, Georgia, Italy, Russian Federation, Serbia, Ukraine, Romania, Denmark, Hungary, Bulgaria
University Hospital, Ghent

Completed

Complement Activation During Hemodialysis in Atypical Hemolytic Uraemic Syndrome as Underlying Kidney Disease

Atypical Hemolytic Uraemic Syndrome

Belgium
Stichting Hemato-Oncologie voor Volwassenen Nederland

Not yet recruiting

Zanubrutinib in Primary Cold Agglutinin Disease (HOVON169CAD)

Lymphoma

Norway, Netherlands, Denmark, Belgium
Alexion

Completed

An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic Syndrome

Atypical Hemolytic-Uremic Syndrome

United Kingdom, United States, France, Italy, Germany, Spain, Belgium
Alexion Pharmaceuticals

Completed

An Open-Label, Multi-Center Clinical Trial of Eculizumab in Pediatric Patients With Atypical Hemolytic-Uremic Syndrome (aHUS)

Atypical Hemolytic-Uremic Syndrome

United Kingdom, Belgium, United States, Germany, Italy, France, Netherlands, Australia, Canada
Alexion Pharmaceuticals

Terminated

aHUS Observational Long Term Follow-Up (LTFU)

Atypical Hemolytic Uremic Syndrome

France, Canada, United States, Belgium, Italy, United Kingdom, Netherlands, Australia, Austria, Germany, Sweden, Switzerland
Swedish Orphan Biovitrum

Suspended

A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With Cold Agglutinin Disease (CAD)

Cold Agglutinin Disease

Spain, Belgium, Norway, United States, Japan, United Kingdom, Netherlands, Canada, Hungary, Austria, Finland, Georgia, Germany, Italy
Alexion
Syneos Health

Recruiting

Atypical Hemolytic-Uremic Syndrome (aHUS) Registry

Atypical Hemolytic-Uremic Syndrome

France, Germany, Israel, Italy, United Kingdom, Canada, United States, Australia, Belgium, Denmark, Korea, Republic of, Poland, Russian Federation, Spain, Taiwan
Francis Corazza

Completed

Monocytic Expression of Heme Oxidase-1 (HO-1) in Sickle Cell Patients and Correlation With the Humoral Immune Response to Vaccine and With Allo-immunization.

Sickle Cell Disease

Belgium
Brugmann University Hospital

Completed

Evaluation of the Hemostatic Potential in Sickle Cell Disease Patients

Sickle Cell Disease

Belgium
Brugmann University Hospital

Completed

Added Value of Speckle Tracking in the Evaluation of Patients With Sickle Cell Disease

Sickle Cell Disease

Belgium
Bioverativ, a Sanofi company

Completed

A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Without A Recent History of Blood Transfusion (Cadenza)

Cold Agglutinin Disease

United States, United Kingdom, Israel, Australia, Spain, Austria, Germany, France, Belgium, Japan, Canada, Netherlands, Italy, Norway
Queen Fabiola Children's University Hospital

Active, not recruiting

Study of Biological Markers in Children With Sickle Cell Disease

Sickle Cell Disease

Belgium
Brugmann University Hospital

Completed

Survey in a Population of Sickle Cell Disease Patients to Evaluate the Transition Between the Queen Fabiola Children Hospital and the CHU Brugmann Hospital, and the Quality of the Hospital Care Within the CHU Brugmann Hospital.

Sickle Cell Disease

Belgium
Alexion Pharmaceuticals, Inc.

Completed

Study of Ravulizumab in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS)

Atypical Hemolytic Uremic Syndrome (aHUS)

Italy, United States, Korea, Republic of, Spain, Germany, Belgium, United Kingdom
Hanane EL KENZ

Completed

Transfusion in Sickle Cell Disease: Risk Factors for Alloimmunization

Sickle Cell Disease

Belgium
Hanane EL KENZ

Withdrawn

Risk Factors for Allo-immunization in Sickle Cell Disease

Sickle Cell Disease

Belgium
Universitair Ziekenhuis Brussel

Recruiting

Autologous Testicular Tissue Transplantation

Hematologic Diseases | Cancer | Sickle Cell Thalassemia

Belgium
Bioverativ, a Sanofi company

Completed

A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion (Cardinal Study)

Agglutinin Disease, Cold

United States, Israel, Australia, Spain, Austria, Germany, Belgium, France, Canada, Italy, Japan, Norway, Netherlands, United Kingdom
Erasme University Hospital

Recruiting

Biological, Genetic and Environmental Involved in the Complications of Sickle Cell Disease

Sickle Cell Disease

Belgium
Brugmann University Hospital

Completed

Single-center Prospective Evaluation of Sickle Cell Patient Care in the CHU Brugmann Emergency Department

Sickle Cell Disease

Belgium
Centre Hospitalier Universitaire Saint Pierre

Recruiting

Clonidine With Morphine in Patient Controlled Analgesia Pump in Vaso-Occlusive Crisis in Sickle Cell Disease Patient

Sickle Cell Disease | Vaso-occlusive Pain Episode in Sickle Cell Disease

Belgium
Hanane EL KENZ

Completed

Transfusion in Sickle Cell Disease: Screening of Sickle Cell Disease Trait in Blood Donors

Sickle Cell Disease | Sickle Cell Trait

Belgium
Hoffmann-La Roche
Chugai Pharmaceutical

Recruiting

A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS) (COMMUTE-p)

Atypical Hemolytic Uremic Syndrome

United States, Belgium, China, France, Spain, Canada, South Africa, Japan, Brazil, Italy, Poland, India, Hungary, Mexico, Israel
Alexion Pharmaceuticals, Inc.

Completed

Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

Atypical Hemolytic Uremic Syndrome (aHUS)

United States, France, Spain, Taiwan, United Kingdom, Australia, Belgium, Germany, Italy, Japan, Korea, Republic of, Russian Federation, Austria, Canada
Queen Fabiola Children's University Hospital

Unknown

Is the Preoperative Preparation of Sickle Cell Patients Optimal: Assessment of Practices and Post-operative Complications

Sickle Cell Disease

Belgium
Academisch Medisch Centrum - Universiteit van Amsterdam...
University Medical Center Groningen; Erasmus Medical Center; Guy's and St Thomas... and other collaborators

Completed

N-Acetylcysteine in Patients With Sickle Cell Disease (NAC)

Sickle Cell Disease

Belgium, Netherlands, United Kingdom
Hoffmann-La Roche
Chugai Pharmaceutical

Recruiting

A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS) (COMMUTE-a)

Atypical Hemolytic Uremic Syndrome

Canada, United States, Japan, France, Spain, Mexico, Peru, Brazil, New Zealand, Belgium, China, Germany, Hungary, Israel, Italy, Poland, South Africa, Turkey, India
AstraZeneca

Completed

PK Study of Ticagrelor in Children Aged Less Than 24 Months, With Sickle Cell Disease (HESTIA4) (HESTIA4)

Sickle Cell Disease

Belgium, United Kingdom, Italy, Spain, Kenya, Lebanon
Pfizer

Completed

Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Study Of PF-04447943, Co-Administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease

Phase 1 Sickle Cell

United States, United Kingdom, Belgium, Netherlands, Italy
Vertex Pharmaceuticals Incorporated
CRISPR Therapeutics

Active, not recruiting

A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease

Sickle Cell Disease | Hemoglobinopathies | Hematological Diseases

United States, Belgium, Canada, France, Germany, Italy, United Kingdom
Novartis Pharmaceuticals

Recruiting

Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study

Sickle Cell Disease

Belgium, Spain, Lebanon, United States, Brazil, France, Italy, Oman, Turkey, Germany, Colombia
Sangart

Withdrawn

Phase 2 Study of MP4CO to Treat Vaso-occlusive Sickle Crisis

Sickle Cell Disease | Anemia, Sickle Cell | Sickle Cell Anemia | Hemoglobin SC Disease | Sickle Cell Disorders | Sickle Cell Hemoglobin C Disease

France, United Kingdom, Netherlands, Turkey, Bahrain, Belgium, Brazil, Lebanon, Qatar
AstraZeneca
Iqvia Pty Ltd

Terminated

Effect of Ticagrelor vs. Placebo in the Reduction of Vaso-occlusive Crises in Pediatric Patients With Sickle Cell Disease (HESTIA3)

Sickle Cell Disease

Italy, Spain, United Kingdom, Belgium, United States, India, South Africa, Brazil, Turkey, Egypt, Ghana, Greece, Kenya, Lebanon, Tanzania, Uganda
Eli Lilly and Company
Daiichi Sankyo, Inc.

Terminated

A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)

Sickle Cell Disease

United Arab Emirates, Italy, United States, Egypt, United Kingdom, Belgium, Turkey, Brazil, Canada, Ghana, Kenya, Lebanon, Oman, Saudi Arabia
Mast Therapeutics, Inc.

Completed

Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC) (EPIC)

Sickle Cell Disease | Vaso-occlusive Crisis

United States, Belgium, Brazil, Dominican Republic, Jamaica, Jordan, Lebanon, Oman, Panama, Spain, Turkey
Agios Pharmaceuticals, Inc.

Recruiting

A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)

Sickle Cell Disease

United Kingdom, United States, Belgium, Netherlands, Germany, Canada, Brazil, France, Israel, Italy, Lebanon, Oman, Ghana, Kenya, Nigeria, Saudi Arabia, Turkey
Cyprus Institute of Neurology and Genetics

Recruiting

Study of the Role of Genetic Modifiers in Hemoglobinopathies (INHERENT)

Sickle Cell Disease | Hemoglobinopathies | Thalassemia Alpha | Thalassemia, Beta

United States, Denmark, Spain, Belgium, Portugal, Congo, The Democratic Republic of the, Greece, Argentina, Brunei Darussalam, Cyprus, Israel, Italy, Nigeria, Malaysia, Angola, Pakistan
Novartis Pharmaceuticals

Active, not recruiting

Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients (STAND)

Sickle Cell Disease (SCD)

United States, United Kingdom, Germany, Spain, Greece, Italy, Brazil, Lebanon, Turkey, Belgium, France, Jordan, India, Finland, Canada, Colombia, Netherlands, Oman, South Africa, Panama, Ghana
Novartis Pharmaceuticals

Recruiting

Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients

Sickle Cell Disease (SCD)

United States, Germany, Spain, Belgium, Italy, Lebanon, Brazil, Colombia, Oman, Switzerland, Turkey, United Kingdom, Canada, India, France
Novartis Pharmaceuticals

Completed

Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Rare Chronic Anemia Patients

Anemia | Hemosiderosis

United States, Germany, Belgium, United Kingdom, Italy, Canada, France
Novartis Pharmaceuticals

Completed

An Extension Study of Iron Chelation Therapy With Deferasirox (ICL670) in β-thalassemia Patients With Transfusional Iron Overload

Transfusional Iron Overload in β-thalassemia

United States, Greece, Argentina, Germany, Belgium, Italy, United Kingdom, France, Tunisia, Canada, Turkey, Brazil
Novartis Pharmaceuticals

Completed

Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload

Myelofibrosis | Sickle Cell Disease | Thalassemia | Diamond Blackfan Anemia

United States, Netherlands, Taiwan, Thailand, Italy, Germany, Spain, Canada, Belgium, Greece, Turkey, United Kingdom
Evangelisches Krankenhaus Düsseldorf
Olympus

Completed

European Novel Motorized Spiral Endoscopy Trial (ENMSET)

Crohn's Disease | Gastrointestinal Hemorrhage | Disorder of Small Intestine | Iron Deficiency Anaemia | Small Bowel Tumors | Intestinal Polyposis Syndrome | Coeliac Disease

Belgium, Germany
Janssen Research & Development, LLC

Active, not recruiting

A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Pregnant Women at High Risk for Early Onset Severe Hemolytic Disease of the Fetus and Newborn (HDFN)

Hemolytic Disease of the Fetus and Newborn

United States, Canada, Netherlands, Belgium, Germany, Spain, Sweden, United Kingdom, Australia
Alexion Pharmaceuticals

Completed

Paroxysmal Nocturnal Hemoglobinuria Human Anti-Human Antibodies Study

Paroxysmal Nocturnal Hemoglobinuria | PNH

Australia, France, United Kingdom, Belgium, Germany, Netherlands, Ireland, United States, Switzerland, Italy
Vifor Pharma
ICON Clinical Research; American Regent, Inc.

Completed

Ferric Carboxymaltose (FCM) Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD) (FIND-CKD)

Chronic Kidney Disease | Iron Deficiency Anaemia

United Kingdom, United States, Australia, Austria, Belgium, Czech Republic, Denmark, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Romania, Spain, Sweden, Turkey

Clinical Trials on Autoimmune Hemolytic Anemia in Belgium

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cyprus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations